Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Trevi Therapeutics CEO Jennifer Good sells $71,575 in stock

Published 22/05/2024, 21:36
TRVI
-

In a recent transaction, Jennifer L. Good, the President and CEO of Trevi Therapeutics, Inc. (NASDAQ:TRVI), sold 25,037 shares of the company's common stock, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $2.8588, totaling approximately $71,575.

The sales took place in multiple transactions with prices ranging from $2.82 to $2.955. The exact number of shares sold at each price point within this range can be provided upon request, as noted in the filing's footnotes.

On the same day, Good also exercised options to acquire 25,037 shares of Trevi Therapeutics common stock at a price of $2.19 per share, amounting to a total transaction value of $54,831. It is noteworthy that these options were part of a grant from July 2, 2014, which vested in stages between June 11, 2015, and June 11, 2018.

Following these transactions, Good holds a total of 213,313 shares directly. These moves are part of her regular financial planning and portfolio management.

Investors often monitor insider transactions as they provide insights into executives' confidence in the company's performance and outlook. However, such transactions can occur for various reasons, and the context provided by the company and its executives can offer additional understanding of these moves.

InvestingPro Insights

Amidst the recent insider transactions by Jennifer L. Good, President and CEO of Trevi Therapeutics, Inc. (NASDAQ:TRVI), investors may find the following InvestingPro Insights particularly informative:

Trevi Therapeutics currently holds a market capitalization of $186.65 million, reflecting its size and scale in the pharmaceutical industry. Despite a challenging period, the company has seen a large price uptick over the last six months, with a 139.47% increase, signaling a significant shift in investor sentiment.

The company's financial health shows some contrasting metrics. An InvestingPro Tip highlights that Trevi Therapeutics holds more cash than debt on its balance sheet, which could be seen as a positive sign of financial stability. Additionally, the company has liquid assets that exceed its short-term obligations, providing some reassurance about its ability to meet immediate financial needs.

However, there are concerns as well. Trevi Therapeutics is quickly burning through its cash and has been noted for weak gross profit margins. Furthermore, analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company will be profitable this year. These concerns are reflected in a negative P/E ratio for the last twelve months as of Q1 2024, standing at -5.58.

For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available that delve deeper into Trevi Therapeutics' financials and projections. For instance, the company's net income is expected to drop this year, and it has not been profitable over the last twelve months. Moreover, the company does not pay a dividend to shareholders, which might be a consideration for income-focused investors.

To explore these insights further and access a total of 10 InvestingPro Tips for Trevi Therapeutics, investors can visit https://www.investing.com/pro/TRVI. Those interested in a subscription can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.